-
公开(公告)号：US08541544B2
公开(公告)日：2013-09-24
申请号：US13126039
申请日：2009-10-27
申请人： Toshihiko Torigoe , Yoshihiko Hirohashi , Noriyuki Satoh , Kenjiro Kamiguchi , Rena Morita , Satoshi Nishizawa , Akari Takahashi
发明人： Toshihiko Torigoe , Yoshihiko Hirohashi , Noriyuki Satoh , Kenjiro Kamiguchi , Rena Morita , Satoshi Nishizawa , Akari Takahashi
CPC分类号： A61K38/177 , C07K7/06 , C12N5/0638 , C12N15/113 , C12N15/1138 , C12N2310/14 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N33/5017 , G01N33/574 , G01N33/57492 , G01N2333/705
摘要： A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
摘要翻译： 用于检测作为感兴趣对象的细胞团中的癌干细胞的分子标记，其中可以在感兴趣的受试者所含的癌干细胞中检测分子标记，但在正常细胞和癌细胞中不能检测到 这与癌症干细胞不同; 通过使用分子标记作为测量来确定感兴趣对象中癌干细胞的存在或不存在的方法; 用于确定癌干细胞的存在或不存在的试剂盒，其包含至少一种用于检测分子标记的试剂; 由分子标记编码的多肽; 能够识别来自分子标记物的基因的表达产物的表位的抗体; 能够抑制分子标记物的表达的核酸; 和包含衍生自分子标记的基因的核酸疫苗。
-
公开(公告)号：US20110262358A1
公开(公告)日：2011-10-27
申请号：US13126039
申请日：2009-10-27
申请人： Toshihiko Torigoe , Yoshihiko Hirohashi , Noriyuki Satoh , Kenjiro Kamiguchi , Rena Morita , Satoshi Nishizawa , Akari Takahashi
发明人： Toshihiko Torigoe , Yoshihiko Hirohashi , Noriyuki Satoh , Kenjiro Kamiguchi , Rena Morita , Satoshi Nishizawa , Akari Takahashi
IPC分类号： A61K49/00 , C12Q1/48 , C12Q1/68 , G01N33/566 , C12Q1/02 , C12N5/095 , C07K7/00 , C07K16/18 , A61K38/02 , A61K39/395 , C07H21/00 , A61K39/00 , C07H21/04 , C07H21/02 , A61K31/7088 , A61P35/00 , A61P43/00 , C12Q1/04
CPC分类号： A61K38/177 , C07K7/06 , C12N5/0638 , C12N15/113 , C12N15/1138 , C12N2310/14 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N33/5017 , G01N33/574 , G01N33/57492 , G01N2333/705
摘要： A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
摘要翻译： 用于检测作为感兴趣对象的细胞团中的癌干细胞的分子标记，其中可以在感兴趣的受试者所含的癌干细胞中检测分子标记，但在正常细胞和癌细胞中不能检测到 这与癌症干细胞不同; 通过使用分子标记作为测量来确定感兴趣对象中癌干细胞的存在或不存在的方法; 用于确定癌干细胞的存在或不存在的试剂盒，其包含至少一种用于检测分子标记的试剂; 由分子标记编码的多肽; 能够识别来自分子标记物的基因的表达产物的表位的抗体; 能够抑制分子标记物的表达的核酸; 和包含衍生自分子标记的基因的核酸疫苗。
-
公开(公告)号：US20100015101A1
公开(公告)日：2010-01-21
申请号：US12294899
申请日：2007-03-27
IPC分类号： A61K35/12 , C12N9/10 , A61K38/45 , C07H21/04 , A61K31/7088 , C12N5/02 , C07K16/00 , C12Q1/48 , A61P35/04 , C12Q1/68
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5158 , A61K2039/57 , C07K16/30 , C07K16/40 , C12Q1/6886 , C12Q2600/158 , G01N33/574 , G01N33/57407
摘要： The invention relates to novel tumor antigen proteins and peptides derived therefrom and use of the same in the filed of cancer immunity. Specifically, the inventions relates to a peptide which comprises a partial peptide derived from Lengsin, BJ-TSA-9, C20orf42, BUB1, C10orf3 or HIFPH3 and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier.
摘要翻译： 本发明涉及新的肿瘤抗原蛋白及其衍生的肽及其在癌症免疫领域中的用途。 具体地，本发明涉及包含衍生自Lengsin，BJ-TSA-9，C20orf42，BUB1，C10orf3或HIFPH3的部分肽并且能够结合HLA抗原并被CTL识别的肽和药物组合物 包括肽和药学上可接受的载体。
-
公开(公告)号：US20100034780A1
公开(公告)日：2010-02-11
申请号：US12096572
申请日：2006-06-27
IPC分类号： A61K38/43 , A61K35/00 , C12N9/00 , C12N5/0784 , C12N5/0783 , C12N5/00 , A61K48/00 , C07K16/40 , C07H21/00
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , G01N33/57434 , G01N2333/99 , G01N2800/52
摘要： The present invention relates to a peptide which comprises a partial peptide derived from AMACR and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier, and the like.
摘要翻译： 本发明涉及一种肽，其包含衍生自AMACR的部分肽并且能够结合HLA抗原并被CTL识别，以及包含该肽和药学上可接受的载体的药物组合物等。
-
公开(公告)号：US07601801B2
公开(公告)日：2009-10-13
申请号：US10563916
申请日：2004-07-07
CPC分类号： C07K7/06 , A61K38/1709 , A61K39/0011 , A61K2039/53 , A61K2039/572 , C07K14/4702 , C07K16/2833
摘要： The present invention provides a partial peptide consisting of 8-11 contiguous amino acids in the amino acid sequence of livin set forth in SEQ ID NO: 1, which binds to HLA-A24 antigen and is recognized by cytotoxic T cells (CTLs), a polynucleotide encoding the peptide, and cancer vaccine comprising the peptide or the polynucleotide.
摘要翻译： 本发明提供由SEQ ID NO：1所示的livin氨基酸序列中的8-11个连续氨基酸组成的部分肽，其结合HLA-A24抗原并被细胞毒性T细胞（CTLs）识别， 编码该肽的多核苷酸，以及包含该肽或该多核苷酸的癌症疫苗。
-
公开(公告)号：US06444800B1
公开(公告)日：2002-09-03
申请号：US09348265
申请日：1999-07-07
申请人： Kokichi Kikuchi , Noriyuki Sato , Toshihiko Torigoe , Hiroeki Sahara , Manabu Suzuki , Junji Hamuro
发明人： Kokichi Kikuchi , Noriyuki Sato , Toshihiko Torigoe , Hiroeki Sahara , Manabu Suzuki , Junji Hamuro
IPC分类号： C07H2102
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00
摘要： A tumor antigen gene is identified by screening a cDNA library derived from a gastric cancer cell line that can induce gastric cancer antigen specific cytotoxic T cell (CTL) by means of hybridization and PCR utilizing an amino acid sequence of peptide fragment of a known gastric cancer antigen protein, introducing a selected cDNA clone into a cell of gastric cancer cell line that cannot induce gastric cancer antigen specific CTL so that the clone should be expressed in the cell, and selecting a transgenic cell that has acquired the ability to induce CTL. According to the present invention, there are provided a protein capable of inducing immune response against human gastric cancer, DNA encoding the protein, as well as vaccine for treatment and prevention of human gastric cancer, and agent for treatment and prevention of human gastric cancer.
-
7.发明申请POTENTIATION OF CELLULAR IMMUNITY USING HISTONE DEACETYLASE (HDAC) INHIBITORS. 审中-公开使用HISTONE脱乙酰壳多糖（HDAC）抑制剂的细胞免疫的潜能。公开(公告)号：US20100093862A1
公开(公告)日：2010-04-15
申请号：US12448073
申请日：2007-12-06
CPC分类号： A61K31/19 , G01N33/6893 , G01N2333/70539 , G01N2333/916 , Y02A50/463
摘要： [Technical Problem] The present invention provides an enhancer of cellular immunity, and provides applications to carcinogenesis or preventive therapy against cancer recurrence, immunotherapy for cancer, treatment for pathogenic microorganism infection, and the like.[Technical Solution] The present invention comprises the substance having an inhibitory activity of histone deacetylase (HDAC) as an active component.
摘要翻译： 技术问题本发明提供细胞免疫的增强剂，提供癌症复发，癌症免疫治疗，病原微生物感染治疗等的癌发生或预防疗法的应用。 技术方案本发明包含具有组蛋白脱乙酰酶（HDAC）作为活性成分的抑制活性的物质。
-
8.发明申请Monoclonal Antibodies Specific to Denatured Human Class I Leucocyte Antigens 审中-公开特异于人类I类白细胞抗原的单克隆抗体公开(公告)号：US20090275055A1
公开(公告)日：2009-11-05
申请号：US11887297
申请日：2006-03-27
IPC分类号： G01N33/567 , C07K16/28 , C12N5/16 , C07H21/04
CPC分类号： G01N33/574 , C07K16/2833 , G01N33/5082 , G01N33/56977 , G01N33/577
摘要： [PROBLEMS] To provide a monoclonal antibody simultaneously detectable the expression of all three kinds of HLA-A, HLA-B and HLA-C heavy chain proteins composing human class I leukocyte antigens (HLA class I) in denatured human tissue samples fixed by formalin and the like.[MEANS FOR SOLVING THE PROBLEMS] It was discovered that injection of denatured recombinant HILA-A*2402 heavy chain proteins to mouse for immunization led to establish HLA class I-specific antibody binding all of denatured HLA-A, B and C. The present invention is a monoclonal antibody specifically binding HLA-A, HLA-B and HLA-C heavy chains composing denatured human class I antigens, wherein said monoclonal antibody is produced by hybridomas (FERM AP-20454) and bound specifically HLA-A, HLA-B and HLA-C heavy chains composing denatured human class I antigens. Furthermore, the present invention is a test reagent for examining denatured human class I leukocyte antigens containing the monoclonal antibody as a major component.
摘要翻译： [问题]提供单克隆抗体同时检测构成人类I类白细胞抗原（HLA I类）的所有三种HLA-A，HLA-B和HLA-C重链蛋白在由福尔马林固定的变性人体组织样品中的表达 等等。 [解决问题的手段]发现将变性重组HILA-A * 2402重链蛋白注射到小鼠进行免疫导致建立HLA I类特异性抗体，其结合所有变性的HLA-A，B和C。本发明 本发明是特异性结合构成变性人I类抗原的HLA-A，HLA-B和HLA-C重链的单克隆抗体，其中所述单克隆抗体由杂交瘤（FERM AP-20454）产生并特异性结合HLA-A，HLA- B和构成变性人I类抗原的HLA-C重链。 此外，本发明是用于检测含有单克隆抗体作为主要成分的变性人I类白细胞抗原的试剂。
-
公开(公告)号：US07030222B2
公开(公告)日：2006-04-18
申请号：US10191322
申请日：2002-07-10
申请人： Kokichi Kikuchi , Noriyuki Sato , Toshihiko Torigoe , Hiroeki Sahara , Manabu Suzuki , Junji Hamuro
发明人： Kokichi Kikuchi , Noriyuki Sato , Toshihiko Torigoe , Hiroeki Sahara , Manabu Suzuki , Junji Hamuro
IPC分类号： C07K5/00
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00
摘要： A tumor antigen gene is identified by screening a cDNA library derived from a gastric cancer cell line that can induce gastric cancer antigen specific cytotoxic T cell (CTL) by means of hybridization and PCR utilizing an amino acid sequence of peptide fragment of a known gastric cancer antigen protein, introducing a selected cDNA clone into a cell of gastric cancer cell line that cannot induce gastric cancer antigen specific CTL so that the clone should be expressed in the cell, and selecting a transgenic cell that has acquired the ability to induce CTL. According to the present invention, there are provided a protein capable of inducing immune response against human gastric cancer, DNA encoding the protein, as well as vaccine for treatment and prevention of human gastric cancer, and agent for treatment and prevention of human gastric cancer.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.032 秒)